Chikungunya vaccine Vimkunya approved by MHRA

The Medicines and Healthcare products Regulatory Agency (MHRA) yesterday approved Vimkunya, a vaccine used to prevent disease caused by the chikungunya virus in people 12 years of age and older.

The marketing authorization was granted to Denmark-based Bavarian Nordic (OMX: BAVA).

The company noted that the UK approval of Vimkunya marks the third authorization of Bavarian Nordic’s chikungunya vaccine, which was cleared by the US Food and Drug Administration (FDA) and the European Commission in February 2025. Bavarian Nordic has also submitted an application to Health Canada, potentially supporting approval of the chikungunya vaccine in the first half of 2026.